miR-19 in blood plasma reflects lung cancer occurrence but is not specifically associated with radon exposure

Abstract

Radon is one of the most powerful carcinogens, particularly in terms of lung cancer onset and development. miRNAs may be considered not only as markers of the ongoing tumorigenesis but also as a hallmark of exposure to radiation, including radon and its progeny. Therefore, the purpose of the present study was to estimate the value of plasma miR-19b-3p level as the prospective marker of the response to radon exposure in lung cancer pathogenesis. A total of 136 subjects were examined, including 49 radon-exposed patients with lung cancer, 37 patients with lung cancer without radon exposure and 50 age/sex matched healthy controls. Total RNA from blood samples was extracted and used to detect miR-19b-3p expression via reverse transcription quantitative-polymerase chain reaction. The 2^-ΔΔCq method was used to quantify the amount of relative miRNA. The plasma level of p53 protein was determined using a Human p53 ELISA kit. Plasma miR-19b-3p level was significantly higher in the patients with lung cancer groups, compared with the healthy control group (P<0.0001). No other statistically significant differences were determined in the expression level of plasma miR-19b-3p between patients diagnosed with lung cancer exposed to radon and not exposed to radon. The expression level of free circulating miR-19b-3p was higher in the group of non-smoking patients with lung cancer, compared with smokers with lung cancer. The miR-19b-3p was 1.4-fold higher in non-smokers than in smokers (P<0.05). No association between plasma levels of p53 protein and miR-19b-3p freely circulating in patients with lung cancer was observed. No other statistically significant differences were determined in the plasma p53 protein level between patients diagnosed with lung cancer exposed and not exposed to radon. These results indicated that detection of miR-19b-3p levels in plasma potentially could be exploited as a noninvasive method for the lung cancer diagnostics. However, this miRNA is not suitable as the precise marker for radon impact.

Keywords: biomarker; lung cancer; miRNA; p53; radon.

Figure 1.

Relative expression level of miR-19b-3p in the plasma of RLC and LC in comparison with C. ****P<0.0001 vs. C. RLC, patients with lung cancer exposed to radon; LC, patients with lung cancer without exposure to radon; C, control group.

Figure 2.

Relative miR-19b-3p expression level in the plasma of patients with lung cancer depending on the smoking status. *P<0.05 vs. Smokers.

Figure 3.

Level of plasma p53 of RLC and LC in comparison with C. *P<0.05 LC vs. C, **P<0.01 RLC vs. C, patients with lung cancer exposed to radon; LC, patients with lung cancer without exposure to radon; C, control group.